TY - JOUR
T1 - M2e-immobilized gold nanoparticles as influenza A vaccine
T2 - Role of soluble M2e and longevity of protection
AU - Tao, Wenqian
AU - Gill, Harvinder S.
N1 - Funding Information:
Authors WT and HSG have submitted a provisional patent to the United States Patent and Trademark Office on the use of gold nanoparticles for influenza vaccination through the Texas Tech University System Office of Research, Commercialization & Federal Relations. Research reported in this publication was supported in part by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R21AI099575 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2015/5/11
Y1 - 2015/5/11
N2 - Influenza virus causes seasonal epidemics and also poses a high risk for pandemics. To develop a broadly cross-protective influenza vaccine we have previously shown that a formulation consisting of the extracellular domain of M2 membrane protein (M2e) immobilized on gold nanoparticles (AuNPs) and soluble CpG as an adjuvant can elicit protective immunity against different influenza A subtypes. The vaccine formulation contains M2e that is immobilized on AuNPs, and an excess amount that is freely dissolved in solution, whose role in inducing protective immunity against virus infection is unclear. Using a mouse model, the current study shows that inclusion of excess soluble M2e antigen along with M2e immobilized on AuNPs is vital for inducing high levels of antibody response, and in providing complete protection against lethal influenza virus challenge. We also show that the vaccine induces long-lasting protection against mortality and morbidity upon lethal challenge with influenza A virus.
AB - Influenza virus causes seasonal epidemics and also poses a high risk for pandemics. To develop a broadly cross-protective influenza vaccine we have previously shown that a formulation consisting of the extracellular domain of M2 membrane protein (M2e) immobilized on gold nanoparticles (AuNPs) and soluble CpG as an adjuvant can elicit protective immunity against different influenza A subtypes. The vaccine formulation contains M2e that is immobilized on AuNPs, and an excess amount that is freely dissolved in solution, whose role in inducing protective immunity against virus infection is unclear. Using a mouse model, the current study shows that inclusion of excess soluble M2e antigen along with M2e immobilized on AuNPs is vital for inducing high levels of antibody response, and in providing complete protection against lethal influenza virus challenge. We also show that the vaccine induces long-lasting protection against mortality and morbidity upon lethal challenge with influenza A virus.
KW - Influenza
KW - Long-term protection
KW - Nanoparticle-conjugated M2e
KW - Soluble M2e
KW - Universal vaccine
UR - http://www.scopus.com/inward/record.url?scp=84928591245&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2015.03.063
DO - 10.1016/j.vaccine.2015.03.063
M3 - Article
C2 - 25842219
AN - SCOPUS:84928591245
SN - 0264-410X
VL - 33
SP - 2307
EP - 2315
JO - Vaccine
JF - Vaccine
IS - 20
ER -